Remarkable advances and remaining questions.
Spot on! Costs an issue as well...
Thank you, yes, you are right!
And it's not just the direct cost of drugs, but also the costs associated with toxicity.
This paper illustrates the old dictum, “More drugs does not necessarily mean better results.”
Have there been other major success stories ? To my limited knowledge, it's been the checkpoint inhibitors in lung and melanoma that have seen massive gains, most others have been incremental. Am I missing others ? Thank you
Imatinib in CML is another major success story… more on that soon in drugdevletter!
Spot on! Costs an issue as well...
Thank you, yes, you are right!
And it's not just the direct cost of drugs, but also the costs associated with toxicity.
This paper illustrates the old dictum, “More drugs does not necessarily mean better results.”
Have there been other major success stories ? To my limited knowledge, it's been the checkpoint inhibitors in lung and melanoma that have seen massive gains, most others have been incremental. Am I missing others ? Thank you
Imatinib in CML is another major success story… more on that soon in drugdevletter!